Screening for Prostate Cancer in 2007: The PSA Era and its Challenges are not Over

European Urology

Volumn 53, Issue 3, 2008, Pages 457-460

  Shariat, Shahrokh F ^a   Karakiewicz, Pierre I ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; CANCER SCREENING; CLINICAL DECISION MAKING; DIAGNOSTIC PROCEDURE; EDITORIAL; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 38749094464     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.11.060     Document Type: Editorial

References (26)

1. Schröder F.H., Carter H.B., Wolters T., et al. Early detection of prostate cancer in 2007 part 1: PSA and PSA kinetics. Eur Urol 53 (2008) 468-477
2. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
3. Punglia R.S., D'Amico A.V., Catalona W.J., Roehl K.A., and Kuntz K.M. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335-342
4. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
5. Berger A.P., Volgger H., Rogatsch H., Strohmeyer D., Steiner H., Klocker H., et al. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens. Prostate 53 (2002) 241-245
6. Catalona W.J., Ramos C.G., Carvalhal G.F., and Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 55 (2000) 791-795
7. Chun F.K., Karakiewicz P.I., Briganti A., et al. Prostate cancer nomograms: an update. Eur Urol 50 (2006) 914-926
8. Master V.A., Chi T., Simko J.P., Weinberg V., and Carroll P.R. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol 174 (2005) 1789-1793
9. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
10. Jones J.S. Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 99 (2007) 1340-1344
11. Epstein J.I., Carmichael M.J., Partin A.W., and Walsh P.C. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 151 (1994) 1587-1592
12. Kattan M.W., Eastham J.A., Wheeler T.M., Maru N., Scardino P.T., Erbersdobler A., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
13. Steyerberg E.W., Roobol M.J., Kattan M.W., van der Kwast T.H., de Koning H.J., and Schröder F.H. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177 (2007) 107-112
14. Vlaev I., and Chater N. Game relativity: how context influences strategic decision making. J Exp Psychol Learn Mem Cogn 32 (2006) 131-149
15. Hogarth R.M., and Karelaia N. Heuristic and linear models of judgment: matching rules and environments. Psychol Rev 114 (2007) 733-758
16. Ross P.L., Gerigk C., Gonen M., Yossepowitch O., Cagiannos I., Sogani P.C., et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 20 (2002) 82-88
17. Carter H.B., Morrell C.H., Pearson J.D., Brant L.J., Plato C.C., Metter E.J., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323-3328
18. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease [see comments]. JAMA 267 (1992) 2215-2220
19. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
20. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
21. Patel D.A., Presti Jr. J.C., McNeal J.E., Gill H., Brooks J.D., and King C.R. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
22. Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
23. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
24. Roobol M.J., Kranse R., de Koning H.J., and Schröder F.H. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology 63 (2004) 309-313
25. Schröder F.H., Roobol M.J., van der Kwast T.H., Kranse R., and Bangma C.H. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465
26. Pinsky P.F., Andriole G., Crawford E.D., Chia D., Kramer B.S., Grubb R., et al. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer 109 (2007) 1689-1695